<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693131</url>
  </required_header>
  <id_info>
    <org_study_id>MND2119H31</org_study_id>
    <secondary_id>JapicCTI-184130</secondary_id>
    <nct_id>NCT03693131</nct_id>
  </id_info>
  <brief_title>Efficacy of MND-2119 in Participants With Hypertriglyceridemia</brief_title>
  <official_title>MND-2119 Phase 3 Study to Evaluate the Efficacy and Safety of MND-2119 Compared to EPADEL CAPSULES 300 in Patients With Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mochida Pharmaceutical Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mochida Pharmaceutical Company, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of MND-2119 compared to
      EPADEL CAPSULES 300 in participants with hypertriglyceridemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MND-2119 is a new formulation of Icosapent. This is a phase 3 study to evaluate the efficacy
      and safety of MND-2119 compared to EPADEL CAPSULES 300 in subjects with hypertriglyceridemia.

      The study period is a total of 22 weeks and is comprised of 8 weeks run-in period, 12 weeks
      treatment period and 2 weeks follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2018</start_date>
  <completion_date type="Actual">June 29, 2019</completion_date>
  <primary_completion_date type="Actual">June 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of change from baseline in serum triglyceride level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in serum total cholesterol level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in serum low-density lipoprotein cholesterol (LDL-C) (direct method) level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in serum LDL-C (indirect method) level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in serum high-density lipoprotein cholesterol (HDL-C) level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in serum non HDL-C level at 12 weeks after the start of study drug administration</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">580</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>MND-2119 2 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MND-2119 2 g, orally, once daily after breakfast for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MND-2119 4 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MND-2119 4 g, orally, once daily after breakfast for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPADEL CAPSULES 300 1.8 g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPADEL CAPSULES 300 0.9 g, orally, twice daily after breakfast and dinner for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPADEL CAPSULES 300 2.7 g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPADEL CAPSULES 300 0.9 g, orally, three-times daily after each meal for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icosapent (MND-2119)</intervention_name>
    <description>Icosapent (MND-2119) capsules.</description>
    <arm_group_label>MND-2119 2 g</arm_group_label>
    <arm_group_label>MND-2119 4 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icosapent (EPADEL CAPSULES 300)</intervention_name>
    <description>Icosapent (EPADEL CAPSULES 300) capsules.</description>
    <arm_group_label>EPADEL CAPSULES 300 1.8 g</arm_group_label>
    <arm_group_label>EPADEL CAPSULES 300 2.7 g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants diagnosed with hypertriglyceridemia.

          2. Participants with values of fasting triglyceride level are 150 mg/dL or higher and
             less than 500 mg/dL.

        Exclusion Criteria:

          1. Participants who have confirmed myocardial infarction and angina pectoris within 6
             months.

          2. Participants who have aortic aneurysm or has received aortic aneurysmectomy within 6
             months.

          3. Participants with, or with a history of, pancreatitis.

          4. Participants who have a history or complication of a clinically significant
             hemorrhagic disease within 6 months.

          5. Participants taking both anti-coagulants and anti-platelets.

          6. Participants receiving dual antiplatelet therapy.

          7. Participants taking direct oral anticoagulants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kohichi Hayashi</last_name>
    <role>Study Director</role>
    <affiliation>Mochida Pharmaceutical Company, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mochida Investigational sites</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 30, 2018</study_first_submitted>
  <study_first_submitted_qc>September 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

